Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Investigational New Drugs

Volumn 31, Issue 2, 2013, Pages 425-434

  Ott, Patrick A ^a,d   Carvajal, Richard D ^b   Pandit Taskar, Neeta ^b   Jungbluth, Achim A ^b   Hoffman, Eric W ^b   Wu, Bor Wen ^c   Bomalaski, John S ^c   Venhaus, Ralph ^b   Pan, Linda ^b   Old, Lloyd J ^b   Pavlick, Anna C ^a   Wolchok, Jedd D ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Polaris Pharmaceuticals   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Arginine deiminase; Argininosuccinate synthetase; Auxotrophy; Melanoma; Metastatic

Indexed keywords

ANTINEOPLASTIC AGENT; ARGININE DEIMINASE POLYETHYLENE GLYCOL CONJUGATE; ARGININOSUCCINATE SYNTHASE; ENZYME ANTIBODY; FLUORODEOXYGLUCOSE F 18; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AMINO ACID BLOOD LEVEL; ANOREXIA; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG UPTAKE; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INJECTION SITE EDEMA; INJECTION SITE PAIN; INJECTION SITE RASH; LIMB PAIN; LYMPHEDEMA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MONOTHERAPY; MYALGIA; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PRURITUS; SEIZURE; SKIN INDURATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME; UVEA MELANOMA;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROLASES; IMMUNOENZYME TECHNIQUES; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TISSUE DISTRIBUTION; UVEAL NEOPLASMS;

EID: 84879550695     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9862-2     Document Type: Article

References (33)

1. Albert VA, Koh HK, Geller AC, Miller DR, Prout MN, Lew RA (1990) Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol 23(2 Pt 1):308-310
2. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24(29):4738-4745
3. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9):2745-2751
4. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M, Thatcher N (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18(1):158-166
5. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7):2105-2116
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur AG (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516. doi: 10.1056/NEJMoa1103782
7. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809-819. doi: 10.1056/NEJMoa1002011
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723. doi: 10.1056/NEJMoa1003466
9. Robert C, Thomas L, Bondarenko I, O'Day S, Webber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526. doi: 10.1056/NEJMoa1104621
10. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK (2011) KIT as a therapeutic target in metastatic melanoma. JAMA: J Am Med Assoc 305(22):2327-2334. doi: 10.1001/jama.2011.746
11. Pasut G, Sergi M, Veronese FM (2008) Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv Drug Deliv Rev 60(1):69-78. doi: 10.1016/j.addr.2007.04.018
12. Dillon BJ, Prieto VG, Curley SA, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2004) Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 100(4):826-833. doi: 10.1002/cncr.20057
13. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2002) Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62(19):5443-5450
14. Sugimura K, Ohno T, Kimura Y, Kimura T, Azuma I (1992) Arginine deiminase gene of an AIDS-associated mycoplasma, Mycoplasma incognitus. Microbiol Immunol 36(6):667-670
15. Philip R, Campbell E, Wheatley DN (2003) Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures. Br J Cancer 88(4):613-623. doi: 10.1038/sj.bjc.66006816600681
16. Shen LJ, Shen WC (2006) Drug evaluation: ADI-PEG-20 - a PEGylated arginine deiminase for arginine-auxotrophic cancers. Curr Opin Mol Ther 8(3):240-248
17. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA (2006) In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 12(23):7126-7131. doi: 10.1158/1078-0432.CCR-06-1101
18. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH (2007) Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 120(4):897-905. doi: 10.1002/ijc.22322
19. Curley SA, Bomalaski JS, Ensor CM, Holtsberg FW, Clark MA (2003) Regression of hepatocellular cancer in a patient treated with arginine deiminase. Hepatogastroenterology 50(53):1214-1216
20. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA, Izzo F (2010) Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 28(13):2220-2226. doi: 10.1200/JCO.2009.26.7765
21. Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA (2004) Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 22(10):1815-1822. doi: 10.1200/JCO.2004.11.120JCO.2004.11.120
22. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, De Rosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF (2005) Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 23(30):7660-7668. doi: 10.1200/JCO.2005.02.0933
23. Feun LG, Savaraj N, Marini A, Wu C, Robles C, Herrera C, Spector S, Luedemann K, Moffat F, Bomalaski J (2006) Phase II study of pegylated arginine deiminase (ADI-PEG20), a novel targeted therapy for melanoma. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 24 (18S (June 20 Supplement)):8045
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92(3):205-216
25. Yang TS, Lu SN, Chao Y, Sheen IS, Lin CC, Wang TE, Chen SC, Wang JH, Liao LY, Thomson JA, Wang-Peng J, Chen PJ, Chen LT (2010) A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients. Br J Cancer 103(7):954-960. doi: 10.1038/sj.bjc.6605856
26. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1):1-10
27. Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wangpaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N (2012) Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer
28. Feun L, Savaraj N (2006) Pegylated arginine deiminase: a novel anticancer enzyme agent. Exp Opin Investig Drugs 15(7):815-822. doi: 10.1517/13543784.15. 7.815
29. Shen LJ, Lin WC, Beloussow K, Shen WC (2003) Resistance to the anti-proliferative activity of recombinant arginine deiminase in cell culture correlates with the endogenous enzyme, argininosuccinate synthetase. Cancer Lett 191(2):165-170
30. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT (2009) Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther 8(12):3223-3233. doi: 10.1158/1535-7163.MCT-09-0794
31. Kuo MT, Savaraj N, Feun LG (2010) Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget 1(4):246-251
32. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, Savaraj N (2008) Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 14(11):1049-1057
33. You M, Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Dinh V, Feun LG (2010) Enhancing melanoma deprivation therapy in melanoma by combining with cisplatin. In: American Associationf for Cancer Research, Annual Meeting